Article
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
Clinical breast cancer - 1 Dec 2014
de Melo Gagliato Debora, Jardim Denis L Fontes, Falchook Gerald, Tang Chad, Zinner Ralph, Wheler Jennifer J, Janku Filip, Subbiah Vivek, Piha-Paul Sarina A, Fu Siqing, Hess Kenneth, Roy-Chowdhuri Sinchita, Moulder Stacy, Gonzalez-Angulo Ana M, Meric-Bernstam Funda, Hong David S
Abstract excerpt
BACKGROUND: c-MET is a receptor tyrosine kinase whose phosphorylation activates important proliferation pathways. MET amplification and mutation have been described in various malignancies, including breast cancer (BC), and c-MET overexpression is associated with worse survival outcomes in patients with BC. We describe MET mutation and amplification rates in a BC cohort of patients referred to a Phase I Unit....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.